A multi-regional, randomized evaluation of the lipid-modifying efficacy and tolerability of anacetrapib added to ongoing statin therapy in patients with hypercholesterolemia or low HDL-C -Density Lipoprotein Cholesterol.

Ballantyne C., Shah S., Sapre A., Ashraf A., Tobias S., ŞAHİN T. , ...More

2016 ESC Cogress, 27 - 31 August 2016

  • Publication Type: Conference Paper / Summary Text